Technical Analysis for NERV - Minerva Neurosciences, Inc

Grade Last Price % Change Price Change
grade F 5.37 4.27% 0.22
NERV closed up 4.27 percent on Friday, May 24, 2019, on 1.72 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical NERV trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 4.27%
Reversal New Lows Setup Bearish Swing Setup 4.27%
Lower Bollinger Band Walk Weakness 4.27%
New 52 Week Low Weakness 4.27%
Wide Bands Range Expansion 4.27%
Below Lower BB Weakness 4.27%

Older signals for NERV ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Drugs Schizophrenia Parkinson's Disease Psychoactive Drugs Major Depressive Disorder Treatment Of Parkinson's Disease Neurochemistry Ketones Antidepressants Central Nervous System Diseases Treatment Of Major Depressive Disorder Treatment Of Central Nervous System Diseases
Is NERV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 12.95
52 Week Low 5.11
Average Volume 141,278
200-Day Moving Average 8.4444
50-Day Moving Average 7.2854
20-Day Moving Average 6.5785
10-Day Moving Average 5.981
Average True Range 0.442
ADX 40.76
+DI 9.4221
-DI 39.3448
Chandelier Exit (Long, 3 ATRs ) 6.304
Chandelier Exit (Short, 3 ATRs ) 6.436
Upper Bollinger Band 8.0583
Lower Bollinger Band 5.0987
Percent B (%b) 0.09
BandWidth 44.988979
MACD Line -0.5439
MACD Signal Line -0.4012
MACD Histogram -0.1427
Fundamentals Value
Market Cap 228.27 Million
Num Shares 42.5 Million
EPS -1.08
Price-to-Earnings (P/E) Ratio -4.97
Price-to-Sales 0.00
Price-to-Book 2.36
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.85
Resistance 3 (R3) 5.82 5.63 5.77
Resistance 2 (R2) 5.63 5.51 5.65 5.74
Resistance 1 (R1) 5.50 5.43 5.57 5.53 5.72
Pivot Point 5.31 5.31 5.34 5.33 5.31
Support 1 (S1) 5.18 5.19 5.25 5.21 5.02
Support 2 (S2) 4.99 5.11 5.01 5.00
Support 3 (S3) 4.86 4.99 4.97
Support 4 (S4) 4.89